Elizabeth T. Chin

Elizabeth T. Chin

Auto-generated profile, based on publicly available information

Elizabeth T. Chin

Stanford University School of Medicine, Stanford, CA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
POPeter Okokhere
Peter Okokhere
ACAndres Colubri
Andres Colubri
CAChukwuemeka Azubike
Chukwuemeka Azubike
CIChristopher Iruolagbe
Christopher Iruolagbe
OOOmoregie Osazuwa
Omoregie Osazuwa
PSPardis C Sabeti
Pardis C Sabeti

26 October 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ECElizabeth T. Chin
Elizabeth T. Chin
DLDavid Leidner
David Leidner
LLLauren Lamson
Lauren Lamson
KLKimberley Lucas
Kimberley Lucas
DSDavid M. Studdert
David M. Studdert
JSJoshua A. Salomon
Joshua A. Salomon
Information regarding the protection conferred by vaccination and previous infection against infection with the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is limited. We evaluated the protection conferred by mRNA vaccines and previous infection against infection with the omicron variant in two high-risk populations: residents and staff in the California state prison system. We used a retrospective cohort design to analyze the risk of infection during the omicron wave using data collected from December 24, 2021, through April 14, 2022. Weighted Cox models were used to compare the effectiveness (measured as 1 minus the hazard ratio) of vaccination and previous infection across combinations of vaccination history (stratified according to the number of mRNA doses received) and infection history (none or infection before or during the period of B.1.617.2 [delta]–variant predominance). A secondary analysis used a rolling matched-cohort design to evaluate the effectiveness of three vaccine doses as compared with two doses. Among 59,794 residents and 16,572 staff, the estimated effectiveness of previous infection against omicron infection among unvaccinated persons who had been infected before or during the period of delta predominance ranged from 16.3% (95% confidence interval [CI], 8.1 to 23.7) to 48.9% (95% CI, 41.6 to 55.3). Depending on previous infection status, the estimated effectiveness of vaccination (relative to being unvaccinated and without previous documented infection) ranged from 18.6% (95% CI, 7.7 to 28.1) to 83.2% (95% CI, 77.7 to 87.4) with two vaccine doses and from 40.9% (95% CI, 31.9 to 48.7) to 87.9% (95% CI, 76.0 to 93.9) with three vaccine doses. Incremental effectiveness estimates of a third (booster) dose (relative to two doses) ranged from 25.0% (95% CI, 16.6 to 32.5) to 57.9% (95% CI, 48.4 to 65.7) among persons who either had not had previous documented infection or had been infected before the period of delta predominance. Our findings in two high-risk populations suggest that mRNA vaccination and previous infection were effective against omicron infection, with lower estimates among those infected before the period of delta predominance. Three vaccine doses offered significantly more protection than two doses, including among previously infected persons.

26 October 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
ECElizabeth T Chin
Elizabeth T Chin
BHBenjamin Q Huynh
Benjamin Q Huynh
LCLloyd Chapman
Lloyd Chapman
MMMatthew Murrill
Matthew Murrill
SBSanjay Basu
Sanjay Basu
NLNathan C Lo
Nathan C Lo
Routine asymptomatic testing strategies for COVID-19 have been proposed to prevent outbreaks in high-risk healthcare environments. We used simulation modeling to evaluate the optimal frequency of viral testing. We found that routine testing substantially reduces risk of outbreaks, but may need to be as frequent as twice weekly.

11 October 2021 in Nature Sustainability
Verified
Journal Article
Open access
PDF file
BHBenjamin Q. Huynh
Benjamin Q. Huynh
LKLaura H. Kwong
Laura H. Kwong
MKMathew V. Kiang
Mathew V. Kiang
ECElizabeth T. Chin
Elizabeth T. Chin
AMAmir M. Mohareb
Amir M. Mohareb
DRDavid H. Rehkopf
David H. Rehkopf
The possibility of a massive oil spill in the Red Sea is increasingly likely. The Safer, a deteriorating oil tanker containing 1.1 million barrels of oil, has been deserted near the coast of Yemen since 2015 and threatens environmental catastrophe to a country presently in a humanitarian crisis. Here, we model the immediate public health impacts of a simulated spill. We estimate that all of Yemen’s imported fuel through its key Red Sea ports would be disrupted and that the anticipated spill could disrupt clean-water supply equivalent to the daily use of 9.0–9.9 million people, food supply for 5.7–8.4 million people and 93–100% of Yemen’s Red Sea fisheries. We also estimate an increased risk of cardiovascular hospitalization from pollution ranging from 5.8 to 42.0% over the duration of the spill. The spill and its potentially disastrous impacts remain entirely preventable through offloading the oil. Our results stress the need for urgent action to avert this looming disaster.

20 October 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
SPSharon L. Paige
Sharon L. Paige
FGFrancisco X. Galdos
Francisco X. Galdos
SLSoah Lee
Soah Lee
ECElizabeth T. Chin
Elizabeth T. Chin
SRSara Ranjbarvaziri
Sara Ranjbarvaziri
Sean WuSean Wu
Sean Wu

22 July 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ECElizabeth T. Chin
Elizabeth T. Chin
DLDavid Leidner
David Leidner
TRTheresa Ryckman
Theresa Ryckman
YLYiran E. Liu
Yiran E. Liu
LPLea Prince
Lea Prince
DSDavid M. Studdert
David M. Studdert
Prisons and jails are high-risk settings for Covid-19, with case and mortality rates far exceeding those in the general community.1 More incarcerated people have died from Covid-19 in U.S. correctional facilities in the past year than died by capital punishment in the past 70 years.2 Some states, including California, have prioritized incarcerated people for vaccination.